[Organization and results of drug vigilance in France].
Pharmacovigilance represents all methods of detection, assessment, information and prevention of adverse drug reactions (ADRs). It mainly involves the post-marketing phase because of the low probability of detecting all possible adverse effects of a drug during pre-marketing development. The most widely used method for pharmacovigilance is spontaneous reporting which is an excellent signal generator but precludes satisfactory calculation of incidence rates. The French Pharmacovigilance System has been set up in 1973; reporting of ADRs has been made mandatory in 1984 for prescribers. This system consists in a network of 30 regional centres under supervision of a coordinating committee at the French Drug Agency. The number of ADR cases received, assessed and recorded by the regional centres is around 10,000 per year; a similar number of cases are reported to the Drug Agency by the pharmaceutical industry. Moreover, Regional Centres work as Drug Information Centres answering more than 23,000 inquiries per year.
Bégaud
B
B
Département de Pharmacologie, C.H.U. de Bordeaux.
Chaslerie
A
A
Haramburu
F
F
D016907:Adverse Drug Reaction Reporting Systems; D004345:Drug Industry; D004346:Drug Information Services; D011307:Drug Prescriptions; D064420:Drug-Related Side Effects and Adverse Reactions; D005602:France; D006801:Humans; D017891:Pharmacoepidemiology / Q000379:methods; D011358:Product Surveillance, Postmarketing
Organisation et résultats de la pharmacovigilance en France.